Welcome to Richmond Pharmacology

Market-leading contract research organisation, specialising in Early Phase Trial Management

Watch our
video

Adaptive
Phase I & II

Taking your drug from
First-In-Human to Proof of Concept in less than nine months.

Learn
more

Bridging
Studies

Cost effective, time efficient and safe protocol design.

Bridging Studies

Thorough & Intensive QTc Studies

From advice by renowned experts to competent study conduct and ECG Analysis. All under one roof

TQT 
Studies

Patient Recruitment

Fast, efficient recruitment using our database of 250,000 active potential participants

Find out
more

UK's leading clinical research organisation

Since 2001, Richmond Pharmacology has conducted over 500 Early Phase Studies, delivering exceptional customer service, and exceeding the expectations of our sponsors. We have significant experience in running a range of patient trials, adding value to the studies by incorporating detailed analysis of the cardiovascular effects of drugs.

We are industry leaders in Adaptive Phase I and II studies, Thorough-QT, Japanese Bridging Studies and Patient Recruitment. Our services span consultancy and concept development through to final reporting.

As a sponsor, you will receive a personal and truly strategic experience and our knowledgeable staff will ensure your trial delivers meaningful results.

Our business ethos is unique:
Our business is sustainable, adaptive to change and is led by the same specialists who founded Richmond Pharmacology nineteen years ago. Our founders are involved in each clinical research trial, so you are assured of a personal service throughout.

We are committed to advancing science and improving patient safety. Our revenues are reinvested in the business and the newly developed, not-for-profit research organisation – Richmond Research Institute. The Institute was born from our partnership with St George’s University London and a mutual desire to expand academic research in key fields of cardiology, hepatology, clinical trial methodology and racial and sex differences in human physiology.

From initial contact to the completion of the study, our drug developers and investors find working with us enjoyable and rewarding.

What makes us special

Work with our experts

Conduct your trial in a cost effective and timely manner

Get in touch today

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more